Royalty Report: Wound Care, Medical, Surgical – Collection: 369299


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Wound Care
  • Medical
  • Surgical
  • Drugs

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 369299

License Grant
Licensor hereby grants to Licensee a license under the Licensed Technology to use and sell the Licensed Products in the Field in the Territory. The license granted does not include any rights of Licensee to grant sublicenses to any Third Party or to have Licensed Products sold by any Third Party on behalf of Licensee, except that Licensee may utilize Sales Representatives.
License Property
U.S. Patent 7,276,255 – Wound and ulcer treatment with super-oxidized water

Licensed Products shall mean only those Licensor proprietary Vashe solution products that are described in Agreement.
Product irrigating solution with the following characteristics.
– packaged in bottles or bags;
– that can be hung on an IV pole and are 'spikeable' via a septum;
– only the 125 ml, 250 ml and 500 ml size pre-filled containers; and
– have a shelf life of 12 months.
– Licensee shall also have the right to sell the foregoing Vashe products that also has
the following characteristics, but only if and as available
– is 'sterile'; and
– have a shelf life greater than 12 months

Field of Use
Vashe® wound therapy product is a solution intended for cleansing, irrigating, moistening, and debriding acute and chronic dermal lesions.  Use of the new product will be emphasized in conjunction with clinical procedures performed with Licensee's ultrasonic systems and gives surgeons and clinicians an expanding line of products for treating wounds.

Field, prior to the market availability of sterile Licensed Product, shall mean the use of the Licensed Product as an irrigating solution specifically for the treatment of human wound care with emphasis on use in conjunction with therapeutic ultrasonic procedures. After market release of sterile Licensed Product.

Field shall mean the use of the Licensed Product, both sterile and non-sterile, as an irrigating solution specifically for the treatment of human wound care principally in conjunction with therapeutic ultrasonic procedures.

IPSCIO Record ID: 304408

License Grant
The Company has an exclusive sublicense to distribute CellerateRX® Activated Collagen® products into the wound care and surgical markets in the United States, Canada and Mexico.
License Property
CellerateRX® is a wound and skin care product for use by surgeons on surgical wounds consisting of a Surgical Powder that is a medical hydrolysate of Type I bovine collagen.  When applied to a surgical wound, the hydrolyzed collagen is ready to aid in the natural wound healing process.

Licensor manufactures the products and owns the CellerateRX registered trademark.

Field of Use
CellerateRX Surgical Powder is a medical hydrolysate of Type I bovine collagen indicated for the management of
Surgical wounds
Traumatic wounds
Partial- and full-thickness wounds
First- and second-degree burns

Licensee will utilize the wound and skin care products for external wounds, including the treatment of external, tunneled or undermined wounds.  These products are used by surgeons in the medical industry. This would include pressure ulcers (Stages I-IV), venous stasis ulcers, diabetic ulcers, ulcers resulting from arterial insufficiency, surgical wounds, traumatic wounds, first and second-degree burns, superficial wounds, cuts, scrapes, skin tears, skin flaps and skin grafts.

The Licensees business is developing, marketing, and distributing wound and skin care products to physicians, hospitals, clinics and post-acute care settings.

IPSCIO Record ID: 299291

License Grant
Licensor grants Licensee of the Cayman Islands an exclusive license under the Licensed Patents and Licensed Technology in both cases to make, have made, use, sell, offer to sell, import, and otherwise distribute and dispose of Products in each case solely in the Field throughout the Territory.

Licensor grants a non-exclusive license to use the Licensor Marks solely in connection with the marketing, promotion and sale of the Product(s) in the Field.

License Property
Licensor is the sole owner of Patent entitled Use of physiologically balanced, ionized, acidic solution in wound healing.

Product shall mean any product comprising any formulation containing hypochlorous acid as its principal active ingredient including that product known as NVC-101.

NVC-101 is a topical antimicrobial that can decrease the bacterial bioburden of chronic wounds.

Field of Use
The Field shall mean, with respect to Products, all commercial uses of the Products for wound care, wound healing, wound cleaning, wound debridement, wound disinfection, wound inflammation, wound exudate management, wound granulation, wound reepithelialization and any other form of wound treatment or wound management including use in surgical wounds and associated disinfection as well as any other treatments that may be adapted to be assisted by reduced pressure, all in humans, but shall exclude for all purposes any products or uses intended for the eye, ear or nose, including the prevention or treatment of any infection thereof.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.